Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade
These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth. 
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. 
Via MarketBeat
Topics Government World Trade
MarketBeat Week in Review – 08/04 - 08/08
Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales 
Via MarketBeat
Topics ETFs Economy World Trade
Why Hims & Hers Stock Sank This Week
The telehealth platform is growing quickly but is in the middle of a legal battle. 
Via The Motley Fool
Topics Lawsuit
Why Novo Nordisk Stock Flew Higher on Friday
It looked good next to a company that has been stealing its thunder lately. 
Via The Motley Fool
Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone. 
Via MarketBeat
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk Stock Investors Need to Know This
The company is using litigation to protect sales of its most popular treatments. 
Via The Motley Fool
Novo Nordisk Is Down 70%: Is the Price Too Low To Ignore?
Investors shouldn't expect a V-shaped recovery. 
Via The Motley Fool
Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?
Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide. 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Top Pick for Affordable Growth Investors
NOVO-NORDISK A/S (NVO) offers affordable growth with strong revenue, earnings growth, and fair valuation, making it a top pick for balanced investors. 
Via Chartmill
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
Via Stocktwits
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Fir
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk
Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance. 
Via Benzinga
Topics Earnings
Why Novo Nordisk Stock Slipped Today
The Danish pharmaceutical company is fighting a competitive war on several fronts. 
Via The Motley Fool
Topics Lawsuit
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. 
Via Stocktwits
Topics Earnings
Law Offices of Howard G. Smith Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.